AJP - Heart BIOPAC complete lab solutions
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 294: H986-H993, 2008. First published December 21, 2007; doi:10.1152/ajpheart.00233.2007
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/2/H986    most recent
00233.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knaapen, P.
Right arrow Articles by Visser, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knaapen, P.
Right arrow Articles by Visser, F. C.

Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy

Paul Knaapen,1 Tjeerd Germans,1 Paolo G. Camici,4 Ornella E. Rimoldi,4 Folkert J. ten Cate,5 Jurrien M. ten Berg,6 Pieter A. Dijkmans,1 Ronald Boellaard,2 Willem G. van Dockum,1 Marco J. W. Götte,1 Jos W. R. Twisk,3 Albert C. van Rossum,1 Adriaan A. Lammertsma,2 and Frans C. Visser1

1Department of Cardiology, 2Department of Nuclear Medicine and PET Research, 3Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Institute for Cardiovascular Research, Amsterdam; 5Department of Cardiology, Thoraxcenter Erasmus Medical Center, Rotterdam; and 6Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; and 4Medical Research Council Clinical Science Center and National Heart and Lung Institute, Imperial College, Hammersmith Campus, London, United Kingdom

Submitted 22 February 2007 ; accepted in final form 17 December 2007

Impaired hyperemic myocardial blood flow (MBF) in hypertrophic cardiomyopathy (HCM), despite normal epicardial coronary arteries, results in microvascular dysfunction. The aim of the present study was to determine the relative contribution of extravascular compressive forces to microvascular dysfunction in HCM. Eighteen patients with symptomatic HCM and normal coronary arteries and 10 age-matched healthy volunteers were studied with PET to quantify resting and hyperemic MBF at a subendocardial and subepicardial level. In HCM patients, MRI was performed to determine left ventricular (LV) mass index (LVMI) and volumes, echocardiography to assess diastolic perfusion time, heart catheterization to measure LV outflow tract gradient (LVOTG) and LV pressures, and serum NH2-terminal pro-brain natriuretic peptide (NT-proBNP) as a biochemical marker of LV wall stress. Hyperemic MBF was blunted in HCM vs. controls (2.26 ± 0.97 vs. 2.93 ± 0.64 ml·min–1·g–1, P < 0.05). In contrast to controls (1.38 ± 0.15 to 1.25 ± 0.19, P = not significant), the endocardial-to-epicardial MBF ratio decreased significantly in HCM during hyperemia (1.20 ± 0.11 to 0.88 ± 0.18, P < 0.01). This pattern was similar for hypertrophied septum and lateral wall. Hyperemic MBF was inversely correlated with LVOTG, NT-proBNP, left atrial volume index, and LVMI (all P < 0.01). Multivariate regression analysis, however, revealed that only LVMI and NT-proBNP were independently related to hyperemic MBF, with greater impact at the subendocardial myocardial layer. Hyperemic MBF is more severely impaired at the subendocardial level in HCM patients. The level of impairment is related to markers of increased hemodynamic LV loading conditions and LV mass. These observations suggest that, in addition to reduced capillary density caused by hypertrophy, extravascular compressive forces contribute to microvascular dysfunction in HCM patients.

hypertrophic cardiomyopathy; outflow tract obstruction; coronary microcirculation; imaging



Address for reprint requests and other correspondence: P. Knaapen, Dept. of Cardiology, 6D 120, VU Univ. Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands (e-mail: p.knaapen{at}vumc.nl)




This article has been cited by other articles:


Home page
JNMHome page
P. G. Camici and O. E. Rimoldi
The Clinical Value of Myocardial Blood Flow Measurement
J. Nucl. Med., July 1, 2009; 50(7): 1076 - 1087.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip
Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
Eur. Heart J., January 9, 2009; (2009) ehn538v1.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
I. Heinonen, S. V. Nesterov, K. Liukko, J. Kemppainen, K. Nagren, M. Luotolahti, P. Virsu, V. Oikonen, P. Nuutila, U. M. Kujala, et al.
Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men
J. Physiol., November 1, 2008; 586(21): 5193 - 5202.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.